Zealand Pharma A/S (LTS:0NZU) Institutional Ownership : 44.74% (As of Jun. 05, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zealand Pharma A/S's institutional ownership is 44.74%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zealand Pharma A/S's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zealand Pharma A/S's Float Percentage Of Total Shares Outstanding is 0.00%.

Zealand Pharma A/S Institutional Ownership Historical Data

The historical data trend for Zealand Pharma A/S's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Institutional Ownership Chart

Zealand Pharma A/S Historical Data

The historical data trend for Zealand Pharma A/S can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	43.67	45.96	45.12	45.39	44.91	45.31	44.73	43.95	44.80	44.74

Zealand Pharma A/S Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Zealand Pharma A/S (LTS:0NZU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (LTS:0NZU) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (LTS:0NZU) Headlines

No Headlines